PRESS RELEASE Paris

Paris, October 29, 2015

Sanofi grew sales and business EPS(1) in Q3 2015

Broad-based sales growth despite Diabetes sales erosion in the U.S.

Group sales(2) increased 3.4% (up 9.2% on a reported basis) to 9,591 million

Diabetes sales decreased 6.6%, as a result of lower U.S. sales of Lantus

Genzyme sales (up 32.7%) showed strong momentum driven by Multiple Sclerosis products

Vaccines sales were up 5.5% mainly driven by Emerging Markets(3)

Animal Health delivered another strong performance (up 9.3%) driven by NexGard

Emerging Markets sales increased by 11.4%

Steady financial performance taking into account higher investments in new products

Operating expenses were 3,816m, up 7.5% at CER

Business net income grew 5.0% at CER (up 8.3% on a reported basis) to 2,096 million

Business EPS increased 6.1% at CER to 1.61 and grew 9.5% on a reported basis

Subsequent event - The financial impact of a voluntary recall announced yesterday for Auvi-Q and Allerject in the U.S. and Canada is under evaluation and will be accounted for in Q4 2015. An initial estimate is a negative impact of approximately 100m on Business Net Income

Significant progress in advancing innovative products

Praluent launched in the U.S. in July and first EU launches underway

New Drug Application for lixisenatide accepted for review by the FDA

Primary endpoint met in second Phase III study for LixiLan in Type 2 diabetes

2015-2018 Diabetes outlook

Accounting for recent market trends, Sanofi now projects global diabetes sales over the period of 2015-2018 to decline at an average annualized rate of between 4% and 8% at CER. Sanofi will mitigate the impact of this revised sales expectation on its business operating income by 2018 and will present the mid-term strategic and financial outlook for the Group on November 6, 2015

2015 financial guidance

Sanofi reaffirms that it expects 2015 Business EPS(1) to be stable to slightly growing versus 2014(4) at constant average exchange rates, barring unforeseen major adverse events

In addition, the positive currency impact on 2015 full-year business EPS is estimated to be between 6% and 8%, under the assumption that exchange rates remain stable in fourth quarter at the average rates of September 2015

Sanofi Chief Executive Officer, Olivier Brandicourt, commented:

The Group showed growth on both top and bottom line in the third quarter driven by strong performance of Genzyme, Vaccines and Emerging Markets. At the same time, we continue to make significant investments to strengthen Sanofi for the future. With the growing adoption of new products such as Aubagio , NexGard , Lemtrada , and Toujeo and the recent launch of Praluent , we have achieved important milestones in our mission to bring innovative medicines to patients. Despite headwinds in our diabetes business, we are confident in Sanofi s long-term prospects and we look forward to sharing our roadmap for the Group on November 6, 2015.

(1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (See Appendix 8 for definitions of financial indicators). The consolidated income statement for Q3 2015 is provided in Appendix 4 and a reconciliation of business net income to IFRS net income reported in Appendix 3; (2) Percentage changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 8 for a definition); (3) See page 8; (4) 2014 business EPS was 5.20

Investor Relations: (+) 33 1 53 77 45 45 - E-mail: IR@sanofi.com - Media Relations: (+) 33 1 53 77 46 46 - E-mail: MR@sanofi.com

Web site: www.sanofi.com Mobile app: SANOFI IR available on the App Store and Google Play

2015 third-quarter and 9-month key figures

2015 third-quarter and 9-month sales

Unless otherwise indicated, all percentage changes in sales in this press release are stated at constant exchange rates(1).

Third quarter sales of Sanofi increased 9.2% on a reported basis to 9,591 million. Exchange rate movements had a positive effect of 5.8 percentage points reflecting mainly the strength of the U.S. dollar and Chinese Yuan against the Euro which largely offset the Venezuelan Bolivar, the Brazilian real and Russian Ruble negative impact. At constant exchange rates, sales increased 3.4%.

Year-to-date sales were 27,779 million, an increase of 12.5% on a reported basis. Exchange rate movements had a favorable effect of 8.9 percentage points.

(5) Including Praluent sales of 4 million in Q3 2015

In the third quarter, sales for Pharmaceuticals increased 2.6% to 7,267 million, driven by Genzyme, which were partially offset by lower sales of Diabetes. Year-to-date sales for Pharmaceuticals were 22,522 million, up 2.8%.

(1) See Appendix 8 for definitions of financial indicators.

In the third quarter, sales of the Diabetes division decreased 6.6% to 1,852 million, reflecting lower sales of Lantus in the U.S. In the U.S., sales of Diabetes were 1,075 million (down 16.4%). Sales of Diabetes outside the U.S. were 777 million, an increase of 8.1%. Strong performance in Emerging Markets ( 373m, up 15.5%) was moderated by stable sales in Western Europe ( 296m, down 0.3%), largely attributable to the entry of glargine biosimilar competition. Year-to-date sales for the Diabetes division were 5,677 million down 4.6%.

Given recent sales trends for the diabetes business and ongoing market dynamics, Sanofi now expects its global diabetes sales to be down between 6% to 7% at CER for 2015. Accounting for recent market trends, Sanofi now projects global diabetes sales over the period of 2015-2018 to decline at an average annualized rate of between 4% and 8% at CER. Approximately half of this revision is linked to insulin glargine and the other half is related to reduced expectations for Afrezza , Lyxumia and BGM (Blood Glucose Monitoring). Sanofi will mitigate the impact of this revised sales expectation on its business operating income by 2018 and will present the mid-term strategic and financial outlook for the Group on November 6, 2015.

Third-quarter sales of Lantus were 1,561 million down 10.8%. In the U.S., sales of Lantus decreased 19.6% to 997 million mainly due to a slowdown of basal insulin market growth, continued higher discounts on Lantus as compared to last year and unfavorable mix effect towards government channels such as Medicaid. In Western Europe, sales of the product decreased 1.4% to 222 million over the period. A biosimilar of Lantus from Eli Lilly was launched in several European markets in the third quarter (including Germany, UK, Netherlands, and Denmark) and in Japan. In Emerging Markets, third-quarter sales of Lantus were up 15.8% to 260 million, driven by China. Year-to-date sales of Lantus decreased 7.3% to 4,854 million.

In September, Sanofi reached a settlement agreement with Eli Lilly. The agreement resolves a U.S. patent infringement lawsuit regarding Lilly s pursuit of regulatory approval for a product that would compete with Lantus SoloSTAR . Sanofi and Lilly agreed to end that lawsuit and to discontinue similar disputes worldwide. Under the agreement, Lilly will pay royalties to Sanofi in exchange for a license to certain Sanofi patents. In the U.S., Lilly will not sell its insulin glargine product before December 15, 2016.

Toujeo , a next-generation basal insulin, was launched in the U.S. market at the end of March and has rapidly obtained market access comparable to Lantus . After the first full two quarters on the market, Toujeo performance is encouraging. The product is trending favorably compared to diabetes analogue launches and now captures around 14% of IMS basal market NBRx share (New-to-Brand Prescriptions) in the U.S. Following EMA approval in April, Toujeo was recently launched in Germany, the U.K., the Netherlands and several Nordic countries where the uptake of the product has shown early promise. Toujeo was also recently launched in Japan and Canada. Total sales of the product were 46 million in the third quarter compared to 13 million in the second quarter of 2015. In the first nine months of 2015, sales of Toujeo were 66 million.

In the third quarter, sales of Amaryl increased 5.7% to 93 million, of which 75 million were generated in Emerging Markets (up 13.6%). Year-to-date sales of Amaryl were up 2.2% to 299

million. Third-quarter sales of Apidra were 88 million, down 4.5%, reflecting lower sales in the U.S. (-17.1% to 34 million). In Emerging Markets, sales of Apidra increased 16.7% to 19 million.

Year-to-date sales of Apidra were up 5.4% to 272 million. Afrezza sales were 2 million and 5 million in the third quarter and the first nine months of 2015, respectively.

In September, the European Commission granted marketing authorization for Praluent (alirocumab, collaboration with Regeneron) for the treatment in certain adult patients of hypercholesterolemia characterized by high level of low-density lipoprotein (LDL) cholesterol. This approval follows the FDA approval received on July 24th, 2015. Praluent was launched in July in the U.S. and, as the product gains market access and awareness develops within the broader medical community, the uptake is expected to be gradual. Initial market access success includes the decision by Express Scripts to add Praluent in a branded preferred Tier 2 formulary position. Sales of Praluent were 4 million in Q3 2015.

Third-quarter sales of Genzyme grew 32.7% to 923 million boosted by the strong performance of Aubagio and the launch progress of Lemtrada . Genzyme recorded another quarter with double-digit sales growth in all territories; U.S. sales increased 40.2% to 431 million, Western Europe sales grew 29.5% to 271 million and Emerging Markets sales were up 27.7% to 135 million. Year-to-date sales of Genzyme increased 30.0% to 2,651 million.

Sales of Rare Diseases were up 13.0% to 630 million in the third-quarter.

Sales of the Gaucher franchise grew 14.3% to 207 million in the third-quarter. In the U.S. sales of this franchise were up 25.0% to 71 million. Sales of Cerezyme were 189 million up 5.1% sustained by Emerging Markets (up 20.0% to 62 million). In the U.S., sales of Cerezyme were down 4.2% reflecting the launch of Cerdelga , the only first-line oral therapy for Gaucher disease type 1 patients. Sales of Cerdelga reached 18 million in the third quarter of which U.S. sales accounted for 16 million. Year-to-date sales of Cerezyme increased 5.4% to 577 million and year-to-date sales of Cerdelga were 44 million.

Third-quarter sales of Fabrazyme grew 18.1% to 147 million. The product recorded strong performance in all territories reflecting new patients accrual; U.S. sales were up 12.1% to 76 million, Western Europe sales grew 21.4% to 34 million, Emerging Markets sales increased 30.8% to 15 million and the Rest of the World sales were up 23.5% to 22 million. Year-to-date sales of Fabrazyme increased 16.0% to 434 million.

Third-quarter sales of Myozyme /Lumizyme were up 10.9% to 162 million driven by the U.S. (up 25.7% to 51 million) which was sustained by the continued accrual of new patients. In Emerging Markets, sales increased 8.7% to 25 million and in Western Europe sales were up 7.2% to 75 million. Year-to-date sales of Myozyme /Lumizyme were 483 million, an increase of 14.5%.

Sales of Multiple Sclerosis products increased 120.2% to 293 million in the third quarter.

Third-quarter sales of Aubagio grew 78.6% to 225 million driven by sales in the U.S. (up 54.0% to 159 million) and Western Europe ( 52 million versus 18 million in the same period of 2014) sustained by strong performance in France. Magnetic resonance imaging data from TEMSO study presented at ECTRIMS in October, demonstrate that Aubagio significantly slowed the brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis. Year-to-date sales of Aubagio increased 81.9% to 599 million.

Sales of Lemtrada were 68 million in the third quarter including 39 million in the U.S. and 22 million in Western Europe (mainly in Germany and the UK). Investigational data from the extension study presented at ECTRIMS support the value proposition of Lemtrada showing that the treatment effects were maintained over five years in the majority of patients with Relapsing Remitting Multiple Sclerosis. Year-to-date sales of Lemtrada were 162 million compared to 18 million in the first nine months of 2014.

Third-quarter sales of Consumer Healthcare (CHC) products were 814 million, an increase of 3.2% driven by Allegra , Lactacyd , and Dorflex . Sales of CHC in the U.S. grew 10.8% to 209 million. Sales of CHC in Emerging Markets were up 2.0% to 393 million driven by a low basis for comparison in Brazil and partially offset by lower sales in China. In Western Europe, sales decreased 7.6% to 146 million impacted by lower sales of Doliprane in France where price decreased in January 2015. In the Rest of the World, sales grew 20.7% to 66 million, reflecting good performance in Australia. Year-to-date sales of CHC reached 2,683 million, an increase of 3.3%.

Sales of Generics increased 6.7% to 452 million in the third quarter driven by sales of the authorized generics of Lovenox in the U.S. as well as Plavix in Japan which was launched by Sanofi and its partner Nichi-Iko Pharmaceuticals at the end of Q2 2015. In Emerging Markets and Western Europe sales of Generics increased 4.5% (to 262 million) and 5.6% (to 135 million), respectively. Year-to-date sales of Generics increased 8.7% to 1,450 million.

Third-quarter sales of Oncology were up 5.4% to 376 million driven by Eloxatin in China and the U.S., Jevtana in the U.S. and Japan. Year-to-date sales of Oncology were 1,123 million, up 0.5%.

Sales of Jevtana increased 9.0% to 78 million in the third quarter led by the U.S. (up 13% to 32 million) and Japan where the product was launched in September 2014. Year-to-date sales of Jevtana were up 10.1% to 237 million.

Sales of Thymoglobulin increased 5.6% to 63 million and 3.8% to 187 million in the third quarter and the first nine months of 2015, respectively.

Third-quarter sales of Eloxatin were up 27.9% (to 58 million) sustained by growth in China and the U.S. Over the same period, sales of Taxotere decreased 3.4% (to 58 million), mainly due to generic competition in Japan. Year-to-date sales of Eloxatin and Taxotere were up 12.5% ( 169 million) and down 17.9% ( 173 million), respectively.

Sales of Mozobil grew 13.8% (to 36 million) and 17.5% (to 105 million) in the third quarter and the first nine months of 2015, respectively.

Established Rx Products

Total sales of Established Rx Products were stable (up 0.1%) at 2,846 million in the third quarter.

Sales of Plavix decreased 5.3% to 446 million in the third quarter reflecting generic competition in Japan in June 2015 (sales in Japan were down 24.7% to 145 million) partially offset by strong performance in China (up 17.6%) and Middle-East. Year-to-date sales of Plavix decreased 0.4% to 1,474 million.

Third-quarter sales of Lovenox were 429 million, up 0.9%. The product recorded a strong performance in Emerging Markets (up 17.0% to 167 million) driven by Africa, Middle-East and Brazil which offset the impact of generic competition in the U.S. (down 61.8% to 16 million). In Western Europe, sales were down 0.9% to 221 million. Sanofi is aware of competitors that have filed

marketing authorization applications for biosimilar enoxaparin with health authorities in Europe. Year-to-date sales of Lovenox were 1,300 million (up 0.6%).

Sales of Renvela /Renagel increased 27.8% to 239 million in the third-quarter driven by growth in the U.S. (up 56.3% to 191 million) which benefited from a low third quarter 2014 comparison due to a limited allotment of generic Renvela tablets granted to Impax. Sales of Renvela /Renagel were down 28.6% to 15 million in Emerging Markets and down 18.8% to 26 million in Western Europe. Generics are currently marketed in some European countries and Sanofi continues to expect potential generic approvals in the U.S. Year-to-date sales of Renvela /Renagel grew 27.0% to 696 million.

Sales of Aprovel /Avapro decreased 8.4% to 167 million in the third quarter reflecting generic competition in Western Europe (down 22.0% to 32 million). In Emerging Markets, sales of the product were down 3.0% to 97 million. The performance in China was partially offset by Latin America. Year-to-date sales of Aprovel /Avapro were 592 million (down 2.4%).

Consolidated sales of Sanofi Pasteur increased 5.5% to 1,717 million in the third quarter driven by Polio/Pertussis/Hib vaccines in Emerging Markets, Menactra in the U.S. and VaxServe (a Sanofi Pasteur company and U.S. specialty supplier of vaccines). Third-quarter sales of Sanofi Pasteur increased 6.5% (to 1,198 million) in the U.S. and 22.3% (to 358 million) in Emerging Markets. Year-to-date sales of Sanofi Pasteur increased 4.0% to 3,301 million.

Third-quarter sales of Influenza vaccines increased 0.3% to 736 million. The performance in the U.S. (up 8.3% to 576 million) reflects Sanofi Pasteur s strategy to offer a range of differentiated influenza vaccines. Sales in Emerging Markets were down 23.9% to 71 million as a result of delayed supply in Mexico. Western Europe sales were down 18% to 73 million. Year-to-date sales of Influenza vaccines decreased 7.1% to 872 million reflecting lower sales in Brazil due to increased supply of the Butantan Institute as a result of the technology transfer agreement with Sanofi Pasteur.

Third-quarter sales of Polio/Pertussis/Hib vaccines were up 17.8% to 327 million driven by Pentaxim , the ramp up of Hexaxim and polio vaccines. In Emerging Markets, sales of Polio/Pertussis/Hib vaccines increased 62.4% to 195 million boosted by sales of Pentaxim and Polio vaccines in China. In the U.S. sales of Polio/Pertussis/Hib vaccines decreased 13.4% to 100 million due to lower sales of Pentacel . Over the period, Shantha sold 5 million of Shan5TM, its pediatric pentavalent vaccine, to global health organizations. Year-to-date sales of Polio/Pertussis/Hib vaccines increased 5.2% to 882 million.

Sales of Menactra grew 17.8% to 239 million in the third quarter reflecting higher U.S. public sector sales. Year-to-date sales of Menactra increased 18.7% to 459 million.

Third-quarter sales of Adult Booster vaccines were 133 million, down 9.9% and reflecting lower sales in Western Europe (down 53.6% to 13 million) due to phasing effect. Year-to-date sales of Adult Booster vaccines were 346 million, an increase of 1.4%.

Third-quarter and Year-to-date sales of Travel and Other Endemic Vaccines declined 8.1% to 96 million and 8.7% to 275 million, respectively.

Sales of Sanofi Pasteur MSD (not consolidated), the joint venture with Merck & Co. in Europe, were 284 million (down 3.7% on a reported basis) and 584 million (down 3.9% on a reported basis) in the third quarter and first nine months, respectively.

Third-quarter sales of Animal Health increased 9.3% to 607 million driven by the continued success of NexGard , Merial s new generation flea and tick product for dogs and also supported by strong performance of our Avian franchise. In the U.S. and Emerging Markets, Animal Health sales grew 10.9% (to 289 million) and 14.0% (to 151 million), respectively. Year-to-date sales of Animal Health increased 12.4% to 1,956 million.

Sales of the Companion Animals segment were up 13.6% to 401 million in the third quarter, as a result of NexGard . The performance of NexGard more than offset the decline in sales of the Frontline products family. Year-to-date sales of Companion Animals segment grew 14.3% to 1,308 million.

Third-quarter sales of the Production Animals segment increased 2.5% to 206 million driven by the Avian business in Emerging Markets. Year-to-date sales of the Production Animals segment grew 8.9% to 648 million.

Net sales by geographic region

(a) World less the U.S., Canada, Western Europe, Japan, South Korea, Australia and New Zealand;

(b) France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark;

(c) Japan, South Korea, Canada, Australia and New Zealand;

Sales in the U.S. increased 2.3% to 3,888 million in the third quarter. The performance of Genzyme (up 40.2%), Vaccines (up 6.5%), CHC (up 10.8%), Animal Health (up 10.9%), and Oncology (up

10.4%) was partially offset by lower sales of Diabetes (down 16.4%). Year-to-date sales in the U.S. grew 1.8% to 10,114 million.

Third-quarter sales in Emerging Markets grew 11.4% to 2,871 million due to the performance of Pharmaceuticals (up 9.9%), Vaccines (up 22.3%) and Animal Health (up 14.0%). In Pharmaceuticals, double-digit growth over the period was delivered by Diabetes (up 15.5%), Genzyme (up 27.7%) Oncology (up 13.8%) and Established Rx products (up 10.7%). In Asia, third-quarter sales were up 17.8% to 964 million, boosted by the performance in China (up 33.2% to 593 million). In China, the performance was largely attributable to Vaccines, Plavix , Lantus , Aprovel and Eloxatin . In Latin America, third-quarter sales were up 7.0% to 697 million. Third-quarter sales in Brazil increased 10.1% to 270 million. Sales in Eastern Europe, Russia and Turkey grew 6.0% to 587 million in the third quarter driven by Turkey and Ukraine. Sales in Russia were up 2.1% to 137 million, reflecting the local economic situation. In Africa and Middle-East, sales grew 11.4% to 562 million. In the Emerging Markets, year-to-date sales increased 8.7% to 8,912 million.

Sales in Western Europe were 1,988 million, down 1.8% in the third quarter. Strong performance of Genzyme (up 29.5%), was offset by lower sales of Established Rx products (-6.3%), CHC (-7.6%) and Vaccines (-24.1%). Year-to-date sales in Western Europe increased 0.6% to 6,017 million.

In the third quarter, sales in Japan decreased 11.4% to 458 million, reflecting generic competition to Plavix (-24.7%) and lower sales of Vaccines (-38.7%). In Japan, year-to-date sales decreased 4.0% to 1,572 million.

Consult Appendix 6 for full overview of Sanofi s R&D pipeline

Regulatory updates since the publication of the second quarter results on July 30, 2015 include the following:

In October, VaxiGrip QIV (Quadrivalent inactivated influenza vaccine) for children three years old or above was submitted to European authorities.

In September, the U.S. Food and Drug Administration (FDA) accepted for filing the New Drug Application (NDA) for lixisenatide, an investigational once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.